- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00086866
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery
Randomized, Open Phase II Study of Immunization With the Recombinant MAGE-3 Protein Combined With Adjuvant AS02B or AS15 in Patients With Unresectable and Progressive Metastatic Cutaneous Melanoma
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells.
PURPOSE: This randomized phase II trial is studying two different regimens of vaccine therapy and comparing them to see how well they work in treating patients with stage III or stage IV melanoma that cannot be removed with surgery.
연구 개요
상태
정황
상세 설명
OBJECTIVES:
Primary
- Compare the objective response rate (complete and partial response) in patients with unresectable stage III or stage IV M1a cutaneous melanoma immunized with vaccine comprising D1/3-MAGE-3-His fusion protein and SB-AS02B adjuvant vs SB-AS15 adjuvant.
- Compare the activity of SB-AS02B adjuvant vs SB-AS15 adjuvant, in terms of maximizing the antigenicity of MAGE-3, in patients treated with these regimens.
- Compare the rate of grade 3/4 vaccine-related toxicity in patients treated with these regimens.
Secondary
- Compare progression-free survival in patients treated with these regimens.
OUTLINE: This is a randomized, open label, parallell-group, multicenter study. Patients are stratified according to disease stage (III in transit vs other stage III vs IV), presence of lesion ≥ 20 mm (yes vs no), and participating center. Patients are randomized to 1 of 2 treatment arms.
Induction therapy
- Arm I: Patients receive immunization comprising D1/3-MAGE-3-His fusion protein and SB-AS02B adjuvant intramuscularly (IM) once weekly on weeks 1, 3, 5, 7, 9, and 11.
- Arm II: Patients receive immunization comprising D1/3-MAGE-3-His fusion protein SB-AS15 adjuvant IM once weekly on weeks 1, 3, 5, 7, 9, and 11.
Patients achieving a clinical complete response (CR), partial response (PR), stable disease (SD), or slow progressive disease (SPD) proceed to maintenance therapy.
- Maintenance therapy: Patients in both arms receive immunization (according to their randomized arm) once weekly on weeks 15, 18, 21, 24, 27, 30, 34, 40, 46, and 52.
Patients maintaining a CR, PR, or SD proceed to long-term treatment.
- Long-term treatment: Beginning 3 months after completion of maintenance therapy, patients in both arms receive immunization (according to their randomized arm) once every 3 months for 4 courses and then once every 6 months for 4 courses.
Treatment continues in both arms in the absence of disease progression that does not correspond to SPD status, unacceptable toxicity, or the diagnosis of an autoimmune disease.
Patients are followed every 12 weeks.
PROJECTED ACCRUAL: A total of 68 patients (34 patients per treatment arm) will be accrued for this study.
연구 유형
등록 (실제)
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
-
Leiden, 네덜란드, 2300 RC
- Leiden University Medical Center
-
Rotterdam, 네덜란드, 3008 AE
- Daniel Den Hoed Cancer Center at Erasmus Medical Center
-
-
-
-
-
Berlin, 독일, D-12200
- Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin
-
Mannheim, 독일, D-68135
- Klinikum der Stadt Mannheim
-
Wuerzburg, 독일, D-97080
- Universitaets - Kinderklinik Wuerzburg
-
-
-
-
-
Brussels, 벨기에, 1000
- Institut Jules Bordet
-
Brussels, 벨기에, 1070
- Hopital Universitaire Erasme
-
-
-
-
-
Barcelona, 스페인, 08036
- Hospital Clínic de Barcelona
-
Madrid, 스페인, 28041
- Hospital Universitario 12 de octubre
-
-
-
-
England
-
London, England, 영국, EC1A 7BE
- Saint Bartholomew's Hospital
-
Manchester, England, 영국, M20 4BX
- Christie Hospital NHS Trust
-
-
-
-
-
Aviano, 이탈리아, 33081
- Centro di Riferimento Oncologico - Aviano
-
Naples, 이탈리아, 80131
- Istituto Nazionale Per Lo Studio E La Cura Dei Tumori
-
Padova, 이탈리아, 35128
- Azienda Ospedaliera di Padova
-
Siena, 이탈리아, 53100
- Universita di SIENA
-
-
-
-
-
Hyeres, 프랑스, 83400
- Clinique Sainte-Marguerite
-
Lille, 프랑스, 59037
- Centre Hospitalier Regional et Universitaire de Lille
-
Montpellier, 프랑스, 34295
- Hopital St. Eloi
-
Nantes, 프랑스, 44093
- CHR Hotel Dieu
-
Paris, 프랑스, 75248
- Institut Curie Hopital
-
Villejuif, 프랑스, F-94805
- Institut Gustave Roussy
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
DISEASE CHARACTERISTICS:
Histologically confirmed cutaneous melanoma
- Unresectable stage III OR stage IV M1a disease
- Documented progressive disease within the past 12 weeks
- Measurable disease
- Skin, soft tissue, or lymph node metastasis allowed provided the disease is not amenable to curative treatment with surgery
- Tumor must express the MAGE-3 gene by reverse transcription polymerase chain reaction analysis (more than 1% of the positive MAGE-3 control included in the assay)
- No visceral metastases within the past 56 days by imaging
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- ECOG 0-1
Life expectancy
- Not specified
Hematopoietic
- Hemoglobin ≥ lower limit of normal (LLN)
- WBC ≥ LLN
- Lymphocyte count ≥ LLN
- Platelet count ≥ LLN
- No bleeding disorders
Hepatic
- Bilirubin ≤ upper limit of normal (ULN)
- Lactic dehydrogenase ≤ ULN
- AST and ALT ≤ 2 times ULN
- PT and aPTT normal
- Hepatitis B surface antigen negative (antibody test may be positive)
- Hepatitis C antibody negative
Renal
- Creatinine ≤ ULN
Cardiovascular
- No clinically significant heart disease (CTC grade III or IV)
Immunologic
- No autoimmune disease (vitiligo allowed)
- No anti-nuclear antibody titer ≥ 1/320 OR equal to 1/160 AND auto-antibodies directed against specific auto-antigens
- No immunodeficiency
- No active infection requiring antibiotic therapy
- HIV negative
Other
- Not pregnant
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 3 months after study participation
- No other malignancy within the past 5 years except surgically cured basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
- No other serious acute or chronic illness requiring concurrent medications
- No psychological, familial, sociological, or geographical condition that would preclude study compliance
PRIOR CONCURRENT THERAPY:
Biologic therapy
- More than 8 weeks since prior adjuvant vaccine therapy
- No prior vaccine therapy containing a MAGE-3 antigen
- No prior vaccine therapy for metastatic melanoma
- No concurrent immunomodulating agents (e.g., BCG)
Chemotherapy
- No prior systemic chemotherapy
- No concurrent chemotherapy
Endocrine therapy
No concurrent corticosteroids
- Concurrent prednisone or equivalent allowed provided the dose is ≤ 40 mg/day and treatment duration is for no more than 3 weeks
- Concurrent inhaled and topical steroids are allowed
Radiotherapy
- No prior radiotherapy to the spleen
No concurrent radiotherapy to > 20% of all existing lesions (i.e., target lesions, non-target lesions, and nonmeasurable lesions)
- Concurrent local low-dose (≤ 20 Grays) radiotherapy allowed
Surgery
- Recovered from prior surgery or biopsy
- No prior organ allograft
- No prior splenectomy
- Concurrent surgery to a limited number of lesions allowed for patients with a complete response, partial response, or stable disease after at least 3 courses of study therapy
Other
- No prior systemic anticancer therapy
- More than 4 weeks since prior isolated limb perfusion therapy
- No other concurrent anticancer therapy
- No other concurrent immunosuppressive agents
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 마스킹: 없음(오픈 라벨)
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
---|
Response rate (complete response and partial response) as assessed by RECIST criteria
|
Vaccine-related toxicity as assessed by CTCAE v3
|
2차 결과 측정
결과 측정 |
---|
무진행 생존
|
Rate of stabilization as assessed by RECIST criteria
|
Rate of mixed response as assessed by RECIST criteria
|
Rate of immune response
|
공동 작업자 및 조사자
수사관
- 연구 의자: Willem H. J. Kruit, MD, PhD, Daniel Den Hoed Cancer Center at Erasmus Medical Center
간행물 및 유용한 링크
일반 간행물
- Ulloa-Montoya F, Louahed J, Dizier B, Gruselle O, Spiessens B, Lehmann FF, Suciu S, Kruit WH, Eggermont AM, Vansteenkiste J, Brichard VG. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. J Clin Oncol. 2013 Jul 1;31(19):2388-95. doi: 10.1200/JCO.2012.44.3762. Epub 2013 May 28.
- Kruit WH, Suciu S, Dreno B, et al.: Immunization with recombinant MAGE-A3 protein combined with adjuvant systems AS15 or AS02B in patients with unresectable and progressive metastatic cutaneous melanoma: A randomized open-label phase II study of the EORTC Melanoma Group (16032- 18031). [Abstract] J Clin Oncol 26 (Suppl 15): A-9065, 2008.
- Louahed J, Gruselle O, Gaulis S, et al.: Expression of defined genes identified by pretreatment tumor profiling: association with clinical responses to the GSK MAGE- A3 immunotherapeutic in metastatic melanoma patients (EORTC 16032-18031). [Abstract] J Clin Oncol 26 (Suppl 15): A-9045, 2008.
- Kruit WH, Suciu S, Dreno B, Mortier L, Robert C, Chiarion-Sileni V, Maio M, Testori A, Dorval T, Grob JJ, Becker JC, Spatz A, Eggermont AM, Louahed J, Lehmann FF, Brichard VG, Keilholz U. Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. J Clin Oncol. 2013 Jul 1;31(19):2413-20. doi: 10.1200/JCO.2012.43.7111. Epub 2013 May 28.
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- EORTC-16032-18031
- EORTC-18031
- EORTC-16032
- GSK-249553/008
- 2004-001937-40 (EudraCT 번호)
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
D1/3-MAGE-3-His 융합 단백질에 대한 임상 시험
-
University of Chicago완전한
-
Ludwig Institute for Cancer Research종료됨
-
Emory UniversityGeorgia Center for Oncology Research & Education아직 모집하지 않음
-
Cliniques universitaires Saint-Luc- Université...종료됨